Phenobarbital embryopathy

disease
On this page

Also known as phenobarbital antenatal exposure

Summary

Phenobarbital embryopathy (MONDO:0016015) is a disease. A subtype of toxic or drug-related embryofetopathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: Unknown (Worldwide)
  • Phenotypes (HPO): 16

Clinical features

Signs & symptoms

Clinical features (HPO)

16 HPO clinical features (Orphanet curated; top 16 by frequency):

HPO IDTermFrequency
HP:0000286EpicanthusFrequent (30-79%)
HP:0000303Mandibular prognathiaFrequent (30-79%)
HP:0000316HypertelorismFrequent (30-79%)
HP:0000369Low-set earsFrequent (30-79%)
HP:0001156BrachydactylyFrequent (30-79%)
HP:0001249Intellectual disabilityFrequent (30-79%)
HP:0001263Global developmental delayFrequent (30-79%)
HP:0008386Aplasia/Hypoplasia of the nailsFrequent (30-79%)
HP:0012808Abnormal nasal baseFrequent (30-79%)
HP:0100333Unilateral cleft lipFrequent (30-79%)
HP:0000047HypospadiasOccasional (5-29%)
HP:0000252MicrocephalyOccasional (5-29%)
HP:0000272Malar flatteningOccasional (5-29%)
HP:0001633Abnormal mitral valve morphologyOccasional (5-29%)
HP:0001636Tetralogy of FallotOccasional (5-29%)
HP:0006265Aplasia/Hypoplasia of fingersOccasional (5-29%)

Identifiers

Disease identifiers

FieldValue
Canonical namephenobarbital embryopathy
Mondo IDMONDO:0016015
Orphanet1919
ICD-111602901948
SNOMED CT715431002
UMLSC4275281
MedGen895102
Is cancer (heuristic)no

Also known as: phenobarbital antenatal exposure

Disease family

Classification path: disease › human disease › disease by developmental or physiological process › disorder of development or morphogenesisdevelopmental defect during embryogenesis › toxic or drug-related embryofetopathy › phenobarbital embryopathy

Related subtypes (21): fetal iodine syndrome, fetal valproate syndrome, aminopterin/methotrexate embryofetopathy, indomethacin embryofetopathy, cocaine embryofetopathy, fetal hydantoin syndrome, fetal trimethadione syndrome, vitamin K-antagonist embryofetopathy, fetal alcohol syndrome, diethylstilbestrol syndrome, fetal methylmercury syndrome, fetal minoxidil syndrome, toluene embryopathy, methimazole embryofetopathy, isotretinoin syndrome, mycophenolate mofetil embryopathy, thalidomide embryopathy, fetal carbamazepine syndrome, acitretin/etretinate embryopathy, fetal phenothiazine syndrome, propylthiouracil embryofetopathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.